GlassScriptPhysician profile
Eman Wahba
NPI 1134127699
$3,680.79
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,114 · 2020: $567.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $473.72 | 2019-2020 | |
| Novo Nordisk INC | $413.61 | 2019-2020 | |
| Glaxosmithkline, LLC. | $401.00 | 2019 | |
| Amgen INC. | $382.04 | 2019-2020 | |
| Amarin Pharma, INC. | $296.24 | 2019-2020 | |
| Pfizer INC. | $295.23 | 2019-2020 | |
| Lilly USA, LLC | $220.86 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $215.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $209.51 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $133.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $128.87 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $82.63 | 2019-2020 | |
| Abbvie INC. | $81.15 | 2019-2020 | |
| Astellas Pharma US INC | $54.30 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $39.73 | 2019 | |
| Arbor Pharmaceuticals, INC. | $29.89 | 2019 | |
| Allergan, INC. | $27.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.68 | 2019 | |
| Seqirus USA INC | $18.45 | 2019 | |
| Genentech USA, INC. | $16.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eman Wahba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.